AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.

The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...

This might drive the stock higher in the near term. The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this ...

SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $19.00 ...

Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...

Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...

Wedbush has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Get AnaptysBio alerts ...